Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The US Food and Drug Administration( FDA) has approved IntelGenx's CPI-300 to treat major depressive disorder.
Subscribe to our email newsletter
CPI-300 is a 450 mg single dose, high-strength formulation of Bupropion hydrochloride (HCl), the active ingredient in Wellbutrin XL.
IntelGenx president and CEO Horst Zerbe said they believe physicians will embrace CPI-300 as a more convenient and safe alternative for their patients requiring high-dose anti-depressant therapy.
"So we now turn our focus towards the commercialization of CPI-300, with the objective of a product launch with a partner by the second quarter of 2012," Zerbe said.